• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Embecta Corp.

    5/9/24 4:45:03 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care
    Get the next $EMBC alert in real time by email
    S-8 1 ss3362761_s8.htm REGISTRATION STATEMENT

     

    As filed with the Securities and Exchange Commission on May 9, 2024

    Registration No. 333-_______

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8 

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    EMBECTA CORP.

    (Exact name of registrant as specified in its charter)

     

     
         
    Delaware   87-1583942

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    300 Kimball Drive, Suite 300

    Parsippany, New Jersey 07054

    (862) 401-0000 

    (Address of Principal Executive Offices)

    EMBECTA CORP. 2022 EMPLOYEE AND DIRECTOR EQUITY-BASED COMPENSATION PLAN

    (Full Title of the Plans)

    Jeff Mann

    SVP, General Counsel, Head of Business Development and Corporate Secretary

    Embecta Corp.

    300 Kimball Drive, Suite 300

    Parsippany, New Jersey 07054

    (862) 401-0000 

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

    With a copy to:

     

    John J. Cannon III

    Allen Overy Shearman Sterling US LLP

    599 Lexington Avenue

    New York, New York 10022

    (212) 848-4000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

                 
    Large accelerated filer   ☒   Accelerated filer   ☐
           
    Non-accelerated filer   ☐   Smaller reporting company   ☐
           
            Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

       

     

     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by Embecta Corp. (the “Registrant”) for the purpose of registering an additional 3,189,000 shares of common stock, $0.01 par value per share (“Common Stock”), of the Registrant, that may be offered or sold under the Embecta Corp. 2022 Employee and Director Equity-Based Compensation Plan (the “Plan”). These additional shares of Common Stock were approved by the Board of Directors of the Registrant on December 11, 2023 and by the stockholders of the Registrant at the Registrant’s annual meeting of stockholders on February 7, 2024, and are additional securities of the same class as other securities for which an original registration statement (File No. 333-264164) on Form S-8 was filed with the Securities and Exchange Commission (the “Commission”) on April 6, 2022. 

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Items 1 and 2 of Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the plan covered by this Registration Statement and as required by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:

     

      a)   The Registrant’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023, filed with the Commission on November 29, 2023 (File No. 001-41186), as amended by the Registrant’s Amendment No.1 to the Annual Report on Form 10-K/A for the fiscal year ended September 30, 2023, filed with the Commission on April 5, 2024 (File No. 001-41186), and the portions of the Registrant’s Proxy Statement on Schedule 14A filed with the Commission on December 19, 2023 (File No. 001-41186) incorporated by reference into such Annual Report;

     

      b)   The description of the Registrant’s Common Stock contained in the information statement filed as Exhibit 99.1 to Amendment No. 1 to the Registrant’s registration statement on Form 10 filed on February 3, 2022 (File No. 001-41186), including any amendment or report filed for the purpose of updating such description;

     

      c)  The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended December 31, 2023, filed with the Commission on February 9, 2024 (File No. 001-41186), and March 31, 2024, filed with the Commission on May 9, 2024 (File No. 001-41186); and

     

      d)   The Registrant’s Current Reports on Form 8-K filed with the Commission since September 30, 2023 (other than portions of those documents furnished or otherwise not deemed to be filed).

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, subsequent to the effective date of this Registration Statement, but prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

       

     

     

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    The Registrant’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) provides that, to the fullest extent permitted by the Delaware General Corporation Law (the “DGCL”), no director will be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty owed to the Registrant or its stockholders as a director.

     

    The Registrant’s Amended and Restated Bylaws (the “Bylaws”), provide that the Registrant must indemnify and hold harmless, to the fullest extent authorized or permitted by the DGCL as it presently exists or may be amended, each person who was or is a party to, or who is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Registrant) (a “Proceeding”) by reason of the fact that he or she is or was a director or an officer of the Registrant, or is or was serving at the request of the Registrant as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust or other enterprise, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any Proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Registrant, and, with respect to any criminal Proceeding, had no reasonable cause to believe such person’s conduct was unlawful. Unless ordered by a court, any indemnification under the Bylaws must be made by the Registrant only as authorized in the specific case upon a determination that indemnification is proper in the circumstances, because such person has met the applicable standard of conduct set forth in the DGCL. With respect to an indemnitee who is a director or officer of the Registrant at the time of such determination, such determination must be made (1) by a majority vote of the directors who are not parties to such proceeding, even though less than a quorum, (2) by a committee of such directors designated by majority vote of such directors, even though less than a quorum, (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion of such independent legal counsel, or (4) by the stockholders. Expenses must be advanced to a covered person under certain circumstances.

    The Registrant maintains a standard policy of officers’ and directors’ liability insurance.

    Section 145 of the DGCL authorizes a corporation to indemnify its directors and officers under certain prescribed circumstances against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding if the director or officer acted in good faith and in a manner the director or officer reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the director or officer’s conduct was unlawful.

    The foregoing is only a general summary of certain aspects of Delaware law and of the Certificate of Incorporation and the Bylaws dealing with indemnification of directors and officers, and does not purport to be complete. It is qualified in its entirety by reference to the detailed provisions of the DGCL and to the Certificate of Incorporation and the Bylaws.

     

       

     

     

    Item 7. Exemption from Registration Claimed.

    Not applicable.

     

    Item 8. Exhibits.

    For the list of exhibits, see the Exhibit Index to this Registration Statement, which is incorporated in this item by reference.

    EXHIBIT INDEX

     

         

    Exhibit

    Number

      Exhibit Description
       
    4.1   Amended and Restated Certificate of Incorporation of Embecta Corp. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on April 6, 2022) (File No. 001-41186)
       
    4.2   Amended and Restated Bylaws of Embecta Corp. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on August 3, 2023) (File No. 001-41186)
       
    5.1*   Opinion of Allen Overy Shearman Sterling US LLP
       
    23.1*   Consent of Independent Registered Public Accounting Firm
       
    23.2*   Consent of Allen Overy Shearman Sterling US LLP (contained in Exhibit 5.1)
       
    24*   Power of Attorney (included on the signature pages of this Registration Statement)
       
    99.1   Embecta Corp. 2022 Employee and Director Equity-Based Compensation Plan (incorporated by reference to Exhibit 10.15 to the Registrant’s Current Report on Form 8-K filed with the Commission on April 6, 2022) (File No. 001-41186)
         
    99.2   Amendment No. 1 to the Embecta Corp. 2022 Employee and Director Equity-Based Compensation Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, filed on February 9, 2024) (File No. 001-41186)
       
    107*   Filing Fee Table

     

    * Filed herewith.

     

       

     

     

    Item 9. Undertakings.

     

    (a)The undersigned Registrant hereby undertakes:

     

    1.To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    i.to include any prospectus required by section 10(a)(3) of the Securities Act;

     

    ii.to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

     

    iii.to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    2.That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3.To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

       

     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Parsippany, State of New Jersey, on the 9th day of May, 2024.

     

    Embecta Corp.

       
    By:  

    /s/ Jeff Mann

        Jeff Mann
        SVP, General Counsel, Head of Business Development and Corporate Secretary

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

     

     

    POWER OF ATTORNEY

    Each person whose signature appears below hereby constitutes and appoints Jeff Mann her or his attorney-in-fact, with the full power of substitution, for her or him in any and all capacities, to sign this registration statement, and any amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act, this registration statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

     

     

    Signature   Title   Date
         

    /s/ Devdatt Kurdikar

      President, Chief Executive Officer, and Director   May 9, 2024
    Devdatt Kurdikar   (Principal Executive Officer)    
         

    /s/ Jacob Elguicze

      Chief Financial Officer   May 9, 2024
    Jacob Elguicze   (Principal Financial Officer)    
         

    /s/ Brian Capone

      Chief Accounting Officer and Corporate Controller   May 9, 2024
    Brian Capone   (Principal Accounting Officer)    
         

    /s/ David F. Melcher

      Director, Chairman of the Board of Directors   May 9, 2024
    David F. Melcher        
         

    /s/ David J. Albritton

      Director   May 9, 2024
    David J. Albritton        
         

    /s/ Carrie L. Anderson

      Director   May 9, 2024
    Carrie L. Anderson        
         

    /s/ Robert J. Hombach

      Director   May 9, 2024
    Robert J. Hombach        

     

    /s/ Milton M. Morris, Ph.D.

      Director   May 9, 2024
    Milton M. Morris, Ph.D.        
         

    /s/ Claire Pomeroy, M.D.

      Director   May 9, 2024
    Claire Pomeroy, M.D.        
         

    /s/ Karen N. Prange

      Director   May 9, 2024
    Karen N. Prange        
         

    /s/ Christopher R. Reidy

      Director   May 9, 2024
    Christopher R. Reidy        
             

     

     

     

    Get the next $EMBC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EMBC

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    More analyst ratings

    $EMBC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be

    2/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    2/5/26 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal First Quarter Financial Results

    PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11

    1/22/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    SEC Filings

    View All

    SEC Form 10-Q filed by Embecta Corp.

    10-Q - Embecta Corp. (0001872789) (Filer)

    2/5/26 11:26:03 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Embecta Corp. (0001872789) (Filer)

    2/5/26 6:54:42 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

    SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)

    1/30/26 1:27:57 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z

    4/A - Embecta Corp. (0001872789) (Issuer)

    12/3/25 4:48:42 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by SVP and CFO Elguicze Jacob

    4/A - Embecta Corp. (0001872789) (Issuer)

    12/3/25 4:45:38 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Roth Anthony M. was granted 32,817 shares and covered exercise/tax liability with 1,881 shares, increasing direct ownership by 188% to 47,415 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    12/1/25 9:31:37 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Embecta Corp. with a new price target

    Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

    4/10/25 12:41:09 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

    12/2/24 6:56:10 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by BTIG Research with a new price target

    BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

    11/27/24 7:22:14 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/12/24 7:08:59 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    3/11/25 7:00:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

    WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

    6/20/24 7:30:00 AM ET
    $EMBC
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    $EMBC
    Financials

    Live finance-specific insights

    View All

    Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be

    2/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    2/5/26 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal First Quarter Financial Results

    PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11

    1/22/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/7/24 4:21:15 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Embecta Corp.

    SC 13G - Embecta Corp. (0001872789) (Subject)

    10/25/24 5:45:30 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care